Clinical Trials | December 11, 2025
Lilly drug cuts risk of disease progression or death by 80% in trial
The company has unveiled the results of pirtobrutinib from its BRUIN CLL-313 study
The company has unveiled the results of pirtobrutinib from its BRUIN CLL-313 study
Roche says its new assay “resolves this challenge by delivering accurate and specific results
The agreement pairs Croda’s global footprint and “smart science” approach with Amino’s precision manufacturing capabilities
Zyrifa is indicated for patients with bone metastases stemming from a wide range of solid tumors
The patented product, developed by Venus Medicine Research Centre (VMRC) for the treatment of multidrug-resistant (MDR) infections, was sold to Cipla in 2019
It's a development that marks a potential breakthrough for people living with the rare and debilitating disease Duchenne muscular dystrophy (DMD)
Columvi combined with gemcitabine and oxaliplatin dramatically extends survival in people with relapsed or refractory diffuse large B-cell lymphoma
This collaboration sets the stage for WuXi Biologics’ first integrated CRDMO center in the region
HYMPAVZI’s safety profile was generally favorable
While Merck can appeal, Halozyme said it expects the order to hold
Subscribe To Our Newsletter & Stay Updated
